Delivery Order V797D70252-36C26125N0499
Award Date
5/14/25
Potential Completion Date
7/14/25
Potential Value
$15K
Federal Agency
Veterans Integrated Service Network 21
Awardee
Gilead Sciences Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Palo Alto, CA 94304, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is a Delivery Order made by the Veterans Integrated Service Network (VISN) 20 of the U.S. Department of Veterans Affairs (VA) to Gilead Sciences Inc. (doing business as Gilead), a large biopharmaceutical company. The contract is for the supply of SUNLENCA 300MG TAB,PKT,5, a pharmaceutical product, under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The contract has a Firm Fixed Price pricing type and a ceiling value of $3,882.02. The contract does...
This federal contract award is for the delivery of VEKLURY REMDESIVIR 437, an emergency pharmaceutical supply, to the Veterans Integrated Service Network 23 (VISN 23) of the U.S. Department of Veterans Affairs (VA). The $89,916.75 firm fixed-price delivery order was awarded to Gilead Sciences Inc., a large biopharmaceutical company, under the GSA Schedule 61-IB for Pharmaceuticals and Drugs. This contract does not have a set-aside designation. Gilead holds a $29.16 million Blanket Purchase...
This is a delivery order contract awarded by the Department of Veterans Affairs to Gilead Sciences Inc. to provide Veklury (remdesivir) for COVID-19 treatment. The contract has a firm fixed price of $155,700.00 and a completion date of January 31, 2021. Gilead is a biopharmaceutical company that provides pharmaceuticals and biologics to government customers through its GSA Schedule contract. Gilead has received numerous federal contracts from the VA to supply antiviral and oncology...
This is a firm fixed-price delivery order awarded by the Department of Veterans Affairs (VA) Veterans Health Administration to Gilead Sciences Inc. (Gilead) for the emergency procurement of the antiviral drug remdesivir (Veklury). The contract has a potential value of $194,625.00 and a completion date of December 31, 2020. This order is placed against Gilead's existing Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB). Gilead, a biopharmaceutical company, has...
This is a delivery order awarded by the Department of Veterans Affairs (VA) Veterans Health Administration to Gilead Sciences Inc., a biopharmaceutical company, for the supply of the COVID-19 antiviral medication Veklury (remdesivir). The order has a firm-fixed price of $155,700.00 and a completion date of October 29, 2021. The contract was awarded on December 9, 2020 and is placed under Gilead's existing General Services Administration (GSA) Multiple Award Schedule contract for...
This is a federal contract awarded by the U.S. Department of Veterans Affairs (VA) to Gilead Sciences Inc. (Gilead), a prominent biopharmaceutical company. The contract, valued at $307,511.22, is a delivery order under Gilead's General Services Administration (GSA) Schedule 61-IB for Pharmaceuticals and Drugs. It provides the VA's Veterans Integrated Service Network (VISN) with the cancer immunotherapy drug YESCARTA. The contract has an ultimate completion date of October 31, 2023. Gilead is the...
This is a delivery order under the GSA Schedule 61-IB for Pharmaceuticals and Drugs, awarded by the U.S. Department of Veterans Affairs (VA) to Gilead Sciences Inc. (Gilead) for the COVID-19 treatment Veklury (remdesivir). The $77,850 fixed-price contract has a performance period ending on March 31, 2021. Gilead, a large biopharmaceutical company, is the sole-source manufacturer of Veklury and a key supplier of critical medications to federal healthcare programs, particularly the VA. The...
This federal contract award, valued at $77,850.00, was made by the Department of Veterans Affairs (VA) to Gilead Sciences Inc. (Gilead) for the delivery of the COVID-19 treatment Remdesivir (100mg). The contract was awarded on December 16, 2020, with an ultimate completion date of December 23, 2020. The contract was issued as a delivery order under Gilead's existing General Services Administration (GSA) Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB). As the...
This is a Firm Fixed Price delivery order awarded by the Department of Veterans Affairs (VA) Veterans Health Administration to Gilead Sciences Inc. under the VA's Pharmaceuticals and Drugs Multiple Award Schedule contract (FSS-61-IB). The contract is for the emergency delivery of YESCARTA-KITE, a medication, to San Antonio, TX. The potential value of the award is $284,904.52, and it has a completion date of March 31, 2020. The contract does not have a set-aside designation. Gilead Sciences...
This is a firm fixed price delivery order contract awarded by the Department of Veterans Affairs (VA) to Genzyme Corporation, doing business as Sanofi Genzyme, a global healthcare and pharmaceutical company. The contract is for the delivery of the specialty pharmaceutical Cerdelga (eliglustat) to support treatment programs for veterans. The contract was awarded under Genzyme's existing $659 million multiple award Federal Supply Schedule (FSS-61-IB) for Pharmaceuticals and Drugs with the VA, as...